The immune system's role in Alzheimer's disease has long been framed around microglia and innate immunity — but mounting evidence implicates the adaptive immune system, particularly cytotoxic T cells, as active contributors to neuronal loss. Understanding precisely how those T cells are recruited and activated could open an entirely new therapeutic window in tauopathy treatment.
Using tauopathy mouse models, researchers demonstrated that conventional type 1 dendritic cells (cDC1s) are essential gatekeepers of CD8+ T cell infiltration into tau-burdened brains. When cDC1 function was genetically ablated, or when antigen cross-presentation — the mechanism by which dendritic cells display extracellular antigens on MHC class I molecules to activate cytotoxic T cells — was disrupted, mice were substantially protected from neurodegeneration. Critically, the brain-resident CD8+ T cells that remained showed limited clonal expansion, fingerprinting impaired peripheral priming rather than reduced trafficking alone. The study also identified secondary lymphoid tissues, not the brain itself, as the likely site where T cells first encounter tau-derived antigens and become activated before migrating centrally.
This work is potentially paradigm-shifting for the tauopathy field. It repositions the spleen and lymph nodes — peripheral immune organs — as upstream control points for neurodegeneration, rather than bystanders. Therapeutically, targeting cDC1s or cross-presentation machinery in the periphery may prove more tractable than intervening inside the central nervous system. That said, important caveats apply: all data are from mouse tauopathy models, and translating dendritic cell biology to human Alzheimer's or frontotemporal dementia is non-trivial given species differences in cDC1 biology. The correlation between CD8+ T cell density and tau pathology severity in human tissue is suggestive but not causal. Replication in human ex vivo systems and eventually clinical biomarker studies will be necessary before this mechanism can be considered a validated therapeutic target.